News & Events

The EMIM addresses the latest developments in morphological, functional and molecular imaging at all scales, including mass spectroscopy, microscopy, and noninvasive imaging in preclinical and exploratory clinical studies. This also includes new strategies for image-guided therapies and theranostics.

With 1000+ international participants, the EMIM has significantly grown while preserving its collaborative, inclusive, and lively atmosphere. It is packed with excellent science and serves as comprehensive and inspiring platform for multidisciplinary exchange and collaboration in this broad and wonderful field of imaging science.

Date: 12-15 March 2024
Venue: Alfândega Congress Centre
Porto, Portugal

“TERACHEM 2022 will offer plenary lectures and presentations on the recent development of existing and new, medically relevant, and interesting radiometals for diagnosis and therapy and their application in chemistry, radiopharmacy and nuclear medicine. TERACHEM 2022 is an ideal occasion to share knowledge and gain a deeper insight into all aspects of radiometals in medicine, not only by attending lectures, oral communications and poster presentations, but also by meeting leading experts from around the world. The Symposium will be held again with the support of the Society of Radiopharmaceutical Sciences (SRS), at the Convention Center in Bressanone (Forum Bressanone), Italy, on September 14 – 17, 2022.

C.S. Cutler (USA)
R. Schibli (Switzerland)
M.C. Giron (Italy)
U. Mazzi (Italy)
R. Rossin (Netherlands)
Professor Carolyn Anderson University of Missouri (USA)
Professor John Valiant McMaster University (Canada)
Professor Frank Rösch University of Mainz (Germany)”


Targeted Alpha Therapy using Terbium and Other Oncological Solutions

Background of the symposium: As part of the strategic planning period 2025-2028 of the ETH Board for the ETH Domain, the Paul Scherrer Institute proposes a large research infrastructure project. The project entails the installation of a new beam line at the High Intensity Proton Accelerator (HIPA) facility at the PSI, with its world-record intensity proton beam, to produce innovative radionuclides for medical purposes particularly for targeted alpha-particle therapy of cancer at the quality and quantity necessary for clinical application. TATTOOS should also comprise laboratories for the aseptic production of novel radionuclides and radiopharmaceuticals that will be made available to hospitals and enable world-first clinical studies.

At this Mini-Symposium world-renowned key-opinion leaders in physics and medicine will highlight the importance of radiolabelled drugs for the diagnosis and treatment of cancer in the coming decades.

The Mini-Symposium is hosted by the Center for Radiopharmaceutical Sciences at the Paul Scherrer Institute.


Date: 26 April 2021

Topics & Invited Speakers

Aim of the event:
  • Provide background of future perspectives regarding radionuclide production at PSI, along with a facility Roadmap proposal.
  • Provide background of new technologies for radionuclide development/production.
  • Highlight the need for such radionuclides towards cancer therapy.